Literature DB >> 17709050

Clinical policy: critical issues in the management of patients presenting to the emergency department with acetaminophen overdose.

Stephen J Wolf, Kennon Heard, Edward P Sloan, Andy S Jagoda.   

Abstract

This clinical policy focuses on critical issues concerning the management of patients presenting to the emergency department (ED) with acetaminophen overdose. The subcommittee reviewed the medical literature relevant to the questions posed. The critical questions are: 1. What are the indications for N-acetylcysteine (NAC) in the acetaminophen overdose patient with a known time of acute ingestion who can be risk stratified by the Rumack-Matthew nomogram? 2. What are the indications for NAC in the acetaminophen overdose patient who cannot be risk stratified by the Rumack-Matthew nomogram? Recommendations are provided on the basis of the strength of evidence of the literature. Level A recommendations represent patient management principles that reflect a high degree of clinical certainty; Level B recommendations represent patient management principles that reflect moderate clinical certainty; and Level C recommendations represent other patient management strategies that are based on preliminary, inconclusive, or conflicting evidence, or based on committee consensus. This guideline is intended for physicians working in EDs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17709050     DOI: 10.1016/j.annemergmed.2007.06.014

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  13 in total

1.  An Unexpected Role of Cholesterol Sulfotransferase and its Regulation in Sensitizing Mice to Acetaminophen-Induced Liver Injury.

Authors:  Yunqi An; Pengcheng Wang; Pengfei Xu; Hung-Chun Tung; Yang Xie; Levent Kirisci; Meishu Xu; Songrong Ren; Xin Tian; Xiaochao Ma; Wen Xie
Journal:  Mol Pharmacol       Date:  2019-04-03       Impact factor: 4.436

2.  Utility of serum lactate to predict drug-overdose fatality.

Authors:  Alex F Manini; Ashish Kumar; Dean Olsen; David Vlahov; Robert S Hoffman
Journal:  Clin Toxicol (Phila)       Date:  2010-08       Impact factor: 4.467

3.  Pharmacy student knowledge retention after completing either a simulated or written patient case.

Authors:  Shaunta' M Ray; Douglas R Wylie; A Shaun Rowe; Eric Heidel; Andrea S Franks
Journal:  Am J Pharm Educ       Date:  2012-06-18       Impact factor: 2.047

4.  Paracetamol toxicity: What would be the implications of a change in UK treatment guidelines?

Authors:  David J McQuade; Paul I Dargan; Jeff Keep; David M Wood
Journal:  Eur J Clin Pharmacol       Date:  2012-04-19       Impact factor: 2.953

Review 5.  Acetylcysteine for acetaminophen poisoning.

Authors:  Kennon J Heard
Journal:  N Engl J Med       Date:  2008-07-17       Impact factor: 91.245

Review 6.  Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.

Authors:  Jonathan G Stine; James H Lewis
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2015-12-25       Impact factor: 3.869

Review 7.  An Update on Treatment of Drug-Induced Liver Injury.

Authors:  Christin Giordano; John Rivas; Xaralambos Zervos
Journal:  J Clin Transl Hepatol       Date:  2014-06-15

8.  Outcomes of patients with acetaminophen-associated toxic hepatitis at a far east poison center.

Authors:  Yi-Chou Hou; Ja-Liang Lin; Wen-Hung Huang; Cheng-Hao Weng; Shen-Yang Lee; Ching-Wei Hsu; I-Kuan Wang; Chih-Chia Liang; Chiz-Tzung Chang; Wey-Ran Lin; Tzung-Hai Yen
Journal:  Springerplus       Date:  2013-12-17

9.  Kind and estimated stocking amount of antidotes for initial treatment for acute poisoning at emergency medical centers in Korea.

Authors:  Chang Hwan Sohn; Seung Mok Ryoo; Kyoung Soo Lim; Won Kim; Hoon Lim; Bum Jin Oh
Journal:  J Korean Med Sci       Date:  2014-11-04       Impact factor: 2.153

Review 10.  Interventions for paracetamol (acetaminophen) overdose.

Authors:  Angela L Chiew; Christian Gluud; Jesper Brok; Nick A Buckley
Journal:  Cochrane Database Syst Rev       Date:  2018-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.